drugset / Trial / NCT01671332
Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
80 enrolled
University of Wisconsin, Madison
Medical College of Wisconsin · collabOhio State University · collabOptimum Therapeutics, LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.
Timeline
- Start
- 2012-06
- Primary completion
- 2015-06-11
- Completion
- 2016-06-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 56 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | suramin | Small molecule | — | Intravenous |